After staring long and hard through the looking glass at Insmed Inc.'s amikacin liposome inhalation suspension (ALIS), the FDA's Antimicrobial Drugs Advisory Committee voted 12-2 Tuesday that the evidence is there to support accelerated approval for ALIS as part of a treatment regimen for adults with nontuberculosis mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) who are out of options.